Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...
FierceBiotech1h
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
BioSpace1h
Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership
The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...
Cramer's Lightning Round: ‘I'd be careful' with Novo Nordisk
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
FierceBiotech22h
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...